Sam Davis
@SamDavisEsq
Followers
1K
Following
3K
Media
111
Statuses
1K
Co-Founder, CXO of CoFormBio | Former CBO & GC @ScipherMedicine - KV, NPV portco | ex-@EQRX VP - a16z, Arch, GV | ex-Big Law (inc. @Goodwinlaw)
Los Angeles (via Boston)
Joined October 2010
We’ve come out of stealth .Website coming soon.Aiming to close partnerships and funding in Q3/Q4.Official announcement at JPM.Race to clinical POC (Ph2a) 18-24 months from launch .Hiring: CMO, Data Science, Clin Dev.DM if you’d like to learn more
3
0
16
RT @bradloncar: My takeaway from this conversation is how it crystallizes the advantage of having a Chinese partner that can get PoC data a….
0
3
0
RT @ohadhammer: New report from Jefferies titled " Shopping in China's Biotech Supermarket" includes some interesting analyses about the Ch….
0
15
0
Impressive for a Dx company to raise in this environment.
Precision medicine startup raises $31M
1
0
1
RT @LifeSciVC: A great post for raising money from VCs. "Best Practices for Pitching, Geared Towards First-Time Founders" - from @Atlas….
0
18
0
Wow! Varda Announces $187 million in Series C Funding to Make Medicines in Space congrats @zebulgar
0
0
2
RT @AndrewE_Dunn: NEW: RevMed will pair its unique library of molecular structures and data with the AI models developed by Iambic Therapeu….
0
2
0
Attention oncology BD leaders 👇.
One of my clients needs a great CBO/BD professional who's strong in asset partnering. It's a public biotech in the oncology space. Please help us find a BD star!!! 🙏.
1
0
1
RT @daphnezohar: As a CEO, the day to day work and mission (patients, team) is really rewarding and what drives so many of us. With that sa….
0
18
0
RT @JMaraganore: “On current trend lines, if we’re not careful, [China] could pass us. They are not just borrowing our ideas and adapting t….
0
2
0
Spot on 👇🏼.
We’re in an incredibly challenging time for biotech fundraising. Endpoints reported on July 3 that megarounds ($100M+) were down 38% in 1H25 vs. the year prior, and that Q2’25 was tracking to be the slowest quarter for private biotech fundraising in over seven years. This also.
0
0
1
RT @drrichjlaw: The number of biotech VC "mega rounds" (described as >$100M) has fallen in H1 2025, compared first 6 months of 2024 (althou….
0
2
0
RT @paras_biotech: 2014-2025 Biotech Valuations:. The decline in private biotech valuations signals a structural, not just cyclical, shift….
0
9
0
RT @princetongb: GOP budget bill's Orphan Cures Act fixes IRA's unintended disincentive for rare disease drug research by exempting multi-i….
0
4
0
RT @chuminhua432: Legend Biotech $LEGN registered a Phase I clinical trial for LUCAR-G19 to treat autoimmune diseases. NCT07049081 https://….
0
1
0
From Oppenheimer: 69 big pharma deals since ‘23 with Chinese biopharma; 6+ mega round deals with newcos with Chinese assets (and many more “stealthcos” with to-be-announced megarounds). Maybe they are just better at execution and giving the customer (big pharma) and patients what
@JohnCendpts @endpts @ky_lahucik Megarounds are never the goal. Only a reflection of how to get long money in deals (they dont write small checks). The long money is taking a pause because of slow exits. It is possible that the solution is to go bigger, not smaller. To insulate from volatile markets and pharma.
0
0
0
RT @IAmBiotech: Following today's passage of the reconciliation package, BIO President & CEO John F. Crowley issued the following statement….
0
1
0
RT @BowTiedBiotech: @JebKeiper What do you think about platform vs assets? Nimbus really is a poster child for how to play the game and ha….
0
1
0